Sibutramine

Generic Name: Sibutramine

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₆ClN

CAS Number: 106650-56-0

Unique Ingredient Identifier: WV5EC51866

Background: Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.

Indication: For the treatment of obesity.

Associated Conditions: Obesity

Clinical Trials

A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects

Phase 1

Completed

Conditions: Obesity

Interventions: Other: sibutramine placebo
Drug: sibutramine

First Posted Date: 2012-05-14

Last Posted Date: 2017-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT01597609

Locations: 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom

The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)

Phase 4

Conditions: Obesity
Polycystic Ovaries Syndrome

Interventions: Drug: Orlistat
Behavioral: Diet and physical exercise
Drug: Sibutramine

First Posted Date: 2011-11-21

Last Posted Date: 2011-11-21

Lead Sponsor: Aristotle University Of Thessaloniki

Target Recruit Count: 200

Registration Number: NCT01475019

Locations: 🇬🇷
Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece

Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine

Not Applicable

Completed

Conditions: Obesity

Interventions: Drug: Sibutramine
Drug: Orlistat

First Posted Date: 2010-08-19

Last Posted Date: 2010-08-19

Lead Sponsor: Gachon University Gil Medical Center

Target Recruit Count: 174

Registration Number: NCT01184560

Locations: 🇰🇷
GachonGill Medical Center, Inchon, Namdong-gu, Korea, Republic of

Studying the Effects of Sibutramine on Eating Behavior

Phase 4

Terminated

Conditions: Obesity

Interventions: Drug: Sibutramine
Drug: Placebo

First Posted Date: 2010-07-27

Last Posted Date: 2017-08-30

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 14

Registration Number: NCT01170364

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

A Weight Loss Study in Overweight Men and Women

Phase 2

Terminated

Conditions: Obesity

Interventions: Drug: LY377604
Drug: Placebo sibutramine
Drug: Placebo Metoprolol
Drug: Sibutramine
Drug: Metoprolol
Drug: Placebo LY377604

First Posted Date: 2009-10-12

Last Posted Date: 2011-06-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 343

Registration Number: NCT00993421

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States